Top 20 Generics Pharma Companies Based On 2019 Revenue

The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of originally marketed products. A report by Global Data says that Indian generic manufacturers are doing particularly well in the generic marketplace, and more and more companies are moving their manufacturing facilities overseas to cut costs. In the list of top 20 companies, Mylan reserved the top position with a revenue of $11.5B in 2019. Our team at PharmaShots has compiled a list of the top 20 generics developing companies based on their 2019 generics revenue.

Generic Segment Revenue: $0.24B

Founded Year: 1980

Market Cap: ~$4.41B

Total Employees: ~6,579

Headquarter: Mumbai, India

Stock Exchange: NSE

Piramal Healthcare is a global pharmaceutical company offering therapies focussed on CNS, cardiovascular, anti-infective, and anti-diabetic. Piramal Healthcare has generated a revenue of $0.24B in 2019 from its generic segment.

Generic Segment Revenue: $0.73B

Founded Year: 1867

Market Cap: ~$0.02B

Total Employees: ~3,400

Headquarter: Surrey, United Kingdom

Stock Exchange: OTCMKTS

Mallinckrodt is a global pharmaceutical company that develops and manufactures therapies for multiple therapy areas including autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy, and neonatal respiratory critical care therapies, and analgesics. Mallinckrodt has generated a revenue of $0.73B in 2019.

Generic Segment Revenue: $0.87B

Founded Year: 1997

Market Cap: ~ $1.21B

Total Employees: ~3,172

Headquarter: Dublin, Ireland

Stock Exchange: NASDAQ

Endo International is an Ireland-based, global pharmaceutical company focusing on generic and branded pharmaceuticals for therapeutic areas that include Endocrinology, Medical Aesthetics, Orthopedics, Urology & Men’s Health. Endo’s Percocet (Oxycodone/acetaminophen) is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain. Endo has generated global sales of $0.87B in 2019.

Generic Segment Revenue: $1.05B

Founded Year: 1959

Market Cap: ~$6.13B

Total Employees: ~12,881

Headquarter: Ahmedabad, India

Stock Exchange: NSE

Torrent Pharma is a pharmaceutical company focused on developing therapies for Cardiovascular, Central Nervous System, GI, Vitamins Minerals Nutritionals (VMN), and Women’s Healthcare. The Company also has a focus on diabetology, pain management, gynecology, oncology, and anti-infective segments. Torrent has generated a sale of $1.05B from the generic portfolio in 2019.

Generic Segment Revenue: $1.20B

Founded Year: 1973

Market Cap: ~$124.6=06B

Total Employees: ~1,00,000

Headquarter: Paris, France

Stock Exchange: EPA

Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacturing, and marketing of therapeutic solutions. The company is focused on Rare Diseases, Multiple Sclerosis, Immunology, Rare Blood Disorder, Oncology, Diabetes, Cardiovascular, Established Prescription Products, Generics, Consumer Healthcare, and Vaccines. Sanofi has generated $1.20B sale from its generic portfolio.

Generic Segment Revenue: $1.30B

Founded Year: 2002 

Market Cap: ~$1.26B

Total Employees: ~5,500

Headquarter: New Jersey, United States

Stock Exchange: NYSE

Amneal Pharmaceuticals is a global company developing and marketing generic and specialty drugs in multiple dosage forms for various diseases. The generic drug has generated a global sale of $1.30B in 2019.

Generic Segment Revenue: $1.41B

Founded Year: 1977

Market Cap: ~$2.02B

Total Employees: ~13,014

Headquarter: Mumbai, India

Stock Exchange: NSE

Glenmark is a global pharmaceutical company focusing on Generics, Specialty, and OTC business in therapy areas like Dermatology, Respiratory, and Oncology including Cardiology, Diabetes, and Oral Contraceptives. In 2019, Glenmark reported sales of $1.41B from its generic segment.

Generic Segment Revenue: $1.69B

Founded Year: 1929

Market Cap: ~$2.04B

Total Employees: ~2,568

Headquarter: Osaka, Japan

Stock Exchange: TYO

Sawai Pharmaceutical is a generic pharmaceutical focus on drugs for multiple therapy areas i.e. cardiovascular, antihyperlipidemic agents, diabetes drugs, anticancer drugs, and OTC drugs. Sawai Pharmaceutical has generated a revenue of $1.69B in 2019.

Generic Segment Revenue: $1.72B

Founded Year: 1895

Market Cap: NA

Total Employees: ~11,100

Headquarter: Bad Vilbel, Germany

Stock Exchange: NA

STADA is an international pharmaceutical company that focuses on Generics and Branded Products. Its branded portfolio includes non-prescription (OTC), prescription (RX), and discretionary prescription (OTX) products. Naxolone (Tilidin Naloxone) is a generic drug targeted for pain. STADA has generated worldwide sales of $1.72B from its generic segment in 2019.

Generic Segment Revenue: $1.83B

Founded Year: 1984

Market Cap: ~$11.32B

Total Employees: ~21,000

Headquarter: Telangana, India

Stock Exchange: NSE

Dr. Reddy’s Laborataries is a global pharmaceutical company with three divided segments Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products. The company focuses on GI, cardiovascular, diabetology, oncology, pain management, and anti-infective. In 2019, Dr. Reddy’s has recorded the sale of $1.83B from its generic segment.

Generic Segment Revenue: $2B

Founded Year: 1968

Market Cap: ~$5.80B

Total Employees: ~24,301

Headquarter: Mumbai, India

Stock Exchange: NSE

Lupin is a pharmaceutical firm involved in developing and delivering a wide range of generic formulations, biosimilar products, and APIs globally. The company holds the 3rd largest position as pharmaceutical-based on global revenue in India and 6th as a generic leader in Japan. The company is focused on multiple therapy areas including Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective, and NSAID space and holds a global leadership position for the Anti-TB segment. Lupin has generated total revenue of $2B from its generic segment in 2019.

Generic Segment Revenue: $2.20B

Founded Year: 1978

Market Cap: ~$7.63B

Total Employees: ~8,600

Headquarter: London, United Kingdom

Stock Exchange: LON

Hikma is a global pharmaceutical firm focusing on the development and marketing of generics, branded products, and injectables anti-infectives, cardiovascular, CNS, diabetes including oncology, pain management, and respiratory. The company’s generic segment has demonstrated the sale of $2.20B in 2019.

Generic Segment Revenue: $2.27B

Founded Year: 1935

Market Cap: ~$8.31B

Total Employees: ~26,000

Headquarter: Mumbai, India

Stock Exchange: NSE

Cipla is a global leading pharmaceutical company ranked at 10th position among the US firms. Cipla is a leading firm in generics that majorly focuses on Cardiology, Oncology, and Diabetology. In Apr’20 Cipla received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation from the FDA. In 2019, Cipla has generated a revenue of $1.79B from its generic segment.

Generic Segment Revenue: $3.06B

Founded Year: 1986

Market Cap: ~$7.09B

Total Employees: ~18,469

Headquarter: Telangana, India

Stock Exchange: NSE

Aurobindo Pharma Limited is a world-leading manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company is focused on therapeutic/product areas encompassing Antibiotics, Antiretrovirals, CVS, CNS, Systemic Gastroenterologicals, Anti-Allergies, Anti-Diabetics, and other therapeutic areas. Aurobindo has generated a total sale of $3.06B in 2019 from its generic segment.

Generic Segment Revenue: $3.29B

Founded Year: 1996

Market Cap: ~$25.63B

Total Employees: ~2,94,134

Headquarter: Bad Homburg, Germany

Stock Exchange: ETR

Fresenius Kabi is a global healthcare company that develops and provides products as well as services for Dialysis, Generic & IV drugs, Biosimilars, Medical Devices in addition to Infusion and Nutrition therapies. Fresenius portfolio has around 90+ intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs that treat multiple disorders. In 2019, the company has generated a total revenue of $3.29B from its generic sales.

Generic Segment Revenue: $4.28B

Founded Year: 1983

Market Cap: ~$18.33B

Total Employees: ~36,000

Headquarter: Mumbai, India

Stock Exchange: NSE

Sun Pharma is the world’s fourth-largest and India’s top generic pharmaceutical company. Sun Pharma’s manufacturing operations are focused on producing generics, branded generics, specialty products, over-the-counter products, anti-retroviral, and active pharmaceutical ingredients (APIs). Apart from this, the firm offers products for several therapy areas such as dermatology, psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, and ophthalmology. Sun Pharma has a pipeline of 98 ANDAs and 5 NDAs awaiting approval from the US FDA. Sun Pharma has reported a global sale of $4.28B in 2019.

Generic Segment Revenue: $9.32B

Founded Year: 1944

Market Cap: ~$11.67B

Total Employees: ~40,039

Headquarter: Petah Tikva, Israel

Stock Exchange: NYSE

Teva is a global pharmaceutical firm leading in generic products with a portfolio consisting of over 35,000 products in every therapy area. The products manufactured include a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Teva has generated a revenue of $9.32B in 2019.

Generic Segment Revenue: $9.73B

Founded Year: 1886

Market Cap: NA

Total Employees: ~26,500

Headquarter: Holzkirchen, Germany

Stock Exchange: NA

Sandoz, a Novartis division is a global leader in developing, manufacturing, and marketing finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The company is organized globally into three divisions Retail Generics, Anti-Infectives, and Biopharmaceuticals. Sandoz is focused on therapies for Cardiovascular, CNS, Dermatology, Gastrointestinal & Hormonal disorders, Metabolism, Oncology, Ophthalmic pain, and Respiratory disorders. In 2019, Sandoz has generated revenue of $9.73B from its generic segment.

Generic Segment Revenue: $10.23B

Founded Year: 1849

Market Cap: ~$232.68B

Total Employees: ~83,000

Headquarter: New York, United States

Stock Exchange: NYSE

Pfizer is a research-based global biopharmaceutical company with a portfolio of Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease, and Consumer Healthcare. Upjohn-Pfizer’s generic business unit has an off-patent branded and generic products business, headquartered in China includes approximately 20 off-patent solid oral dose brands as well as certain generic products. In 2019, Pfizer’s generic segment has generated a global sales revenue of $10.23B.

Generic Segment Revenue: $11.5B

Founded Year: 1961

Market Cap: ~21.57B

Total Employees: ~35000

Headquarter: Pennsylvania, United States

Stock Exchange: NASDAQ

Mylan is a global pharmaceutical company focused on manufacturing of prescription generic, branded generic, brand-name including biosimilar drugs and OTC drugs for multiple diseases. Mylan focuses on drugs that are challenging to formulate and manufacture and usually have longer product life cycles than usual generic pharmaceuticals. Mylan has generated a revenue of $11.5B in 2019 from its generic segment. In Sep’19 Mylan launched its Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC.

Related Post: Top 20 Generics Pharma Companies Based On 2018 Revenue

The post Top 20 Generics Pharma Companies Based On 2019 Revenue first appeared on PharmaShots.

Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Shots:

  • Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of ​Rs. 39/tablet
  • Cipla receives the DCGI approval for Ciplenza (favipiravir, 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the first week of August priced at Rs 68/ tablet
  • Moreover, Brinton gets DCGI approval drug favipiravir under the brand name Faviton (Rs 59/ tablet) for the treatment of COVID-19 patients. Faviton is a generic version of Avigan of Fujifilm Toyama, a subsidiary of Fujifilm Corporation

Cipla, Jenburkt, Brinton­ read full press release/ article | Ref: Cipla, Jenburkt, Brinton | Image: Pharmashots